Vizgen Announces Key Leadership Appointments to Support Growing Momentum and Continued Global Expansion of Single Cell Spatial Genomics Platform

2023-11-30

高管变更

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced an expansion of its leadership team with the appointment of two highly accomplished industry leaders. The company has named Seth Benson, Chief Financial Officer, and Sara Mackey, Vice President Marketing. "We welcome Seth and Sara to our Vizgen family and know their experience, expertise and business acumen will be instrumental as we continue working towards a future where every disease has a map and every cure has a path,” said Terry Lo, President and CEO of Vizgen. “This is an exciting time for Vizgen, and we look forward to working with our new, expanded team to develop and broaden the reach of tools that demonstrate the possibilities of in situ single cell spatial genomics.” Seth Benson has over 20 years of experience in finance, strategy and operations. He has held various leadership roles at high growth life sciences companies and commercial labs, including Akoya Biosciences where he helped grow the company to more than 300 people and played a pivotal role in its IPO. Prior to joining Vizgen, Benson led the global finance organization at Invaio Sciences. His career began in management consulting at Accenture then transitioned to investment banking roles at Merrill Lynch and Morgan Stanley. Benson received his BS in Biology from Duke University and his MBA from the Kellogg School of Management. Sara Mackey is an experienced business leader with a demonstrated expertise in working within the life science industry for over 25 years. Prior to joining Vizgen, she served as Vice President of Biopharma and Corporate Strategy at Advanced Instruments where she played a key role in helping to facilitate the sale of the company to Patricia Industries in 2020. Mackey then led the acquisition of SAL Scientific and Solentim, further pivoting the company and portfolio to high-growth market segments. Earlier in her career, she served as Director of Product Marketing at Cell Signaling Technology, Product Portfolio Director of Drug Discovery and Development at PerkinElmer and held various marketing leadership roles at Thermo Fisher Scientific. Mackey is skilled in organic and inorganic growth strategy, business transformation, product commercialization and new market development. She holds a BSc in Biomedical Science and Pharmacology from the University of Bradford. About Vizgen® Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE® Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to . Connect on social media Twitter, LinkedIn and Facebook.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构